Researchers are studying why the energy factories are moving between cells and whether the process can be harnessed to treat ...

A multi-institutional study led by Moffitt Cancer Center found that percutaneous hepatic perfusion using a melphalan hepatic ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Scientists have attempted to map the human cell since the first microscope was invented more than 400 years ago. But many ...

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

By mapping the subcellular architecture and protein interactions within cells, researchers can better understand how mutations contribute to pediatric cancers and other conditions.

The Lupus Foundation of America (LFA) is excited to share that enrollment for the MiSLE (Mesenchymal Stromal Cells in ...

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn ... Lupus is an autoimmune disease in which the immune system attacks healthy tissue in the body instead ...

Saphnelo (anifrolumab-fnia) is a prescription drug ... Because Saphnelo affects the immune system, it may increase the risk of infections. Serious infections, including pneumonia and, in some ...

Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...